Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PTN | Common stock | Award | $0 | +705K | +9.4% | $0.00 | 8.2M | Jun 22, 2021 | Direct | F1 |
transaction | PTN | Common stock | Award | $0 | +250K | +3.05% | $0.00 | 8.45M | Jun 22, 2021 | Direct | F2 |
transaction | PTN | Common stock | Award | $0 | +52.9K | +0.63% | $0.00 | 8.5M | Jun 22, 2021 | Direct | F3 |
transaction | PTN | Common stock | Award | $0 | +126K | +1.48% | $0.00 | 8.63M | Jun 22, 2021 | Direct | F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PTN | Stock option (right to buy) | Award | $0 | +575K | $0.00 | 575K | Jun 22, 2021 | Common stock | 575K | $0.55 | Direct | F5 | |
transaction | PTN | Stock option (right to buy) | Award | $0 | +209K | +497483.33% | $0.00 | 209K | Jun 22, 2021 | Common stock | 209K | $0.58 | Direct | F6 |
Id | Content |
---|---|
F1 | Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2022. |
F2 | Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest only if within two years of the date of grant for a twenty consecutive trading day period the price of common stock on the NYSE American for Palatin Technologies, Inc. closes at $2.00 per share or greater. |
F3 | Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of share units for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |
F4 | Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of share units for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |
F5 | The options vest at the rate of 25% per year, starting on June 22, 2022. |
F6 | Stock options granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. The performance condition stock option grant, made June 16, 2020, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of stock option shares for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |